Health Catalyst, Inc. (HCAT) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended September 30, 2025. Health Catalyst, Inc. is a provider of data and analytics technology and services to healthcare organizations. The company operates in two segments: Technology (cloud-based data platform and analytics applications) and Professional Services (analytics, implementation, and advisory services). The company is currently navigating a strategic migration of clients from its legacy DOS platform to the new "Health Catalyst Ignite" platform.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $76.3 million | $76.4 million | $236.5 million | $227.0 million |
| Net Loss | $(22.2) million | $(14.7) million | $(86.9) million | $(48.8) million |
| Adjusted EBITDA | $12.0 million | $7.3 million | $27.6 million | $18.2 million |
| Gross Margin (GAAP) | 39% | 36% | 38% | 38% |
| Adjusted Gross Margin | 53% | 48% | 50% | 50% |
| Cash & Short-term Investments | $91.5 million (as of Sept 30, 2025) | |||
| Long-term Debt (Net) | $151.5 million (Term Loan Facility) |
Material Changes vs. Prior Period
- Revenue Stagnation: Q3 revenue remained flat year-over-year ($76.3M vs $76.4M). Technology revenue grew 7% to $52.1M, while Professional Services revenue declined 12% to $24.3M due to lower utilization rates and the exit of pilot ambulatory operations.
- Increased Net Loss: The Q3 net loss widened to $22.2M from $14.7M. This was primarily driven by $6.9 million in non-recurring lease-related impairment charges and $4.8 million in restructuring costs.
- Goodwill Impairment: A significant non-cash goodwill impairment charge of $28.8 million was recorded in Q2 2025 (impacting YTD results), triggered by declines in stock price and downward revenue forecast revisions. No impairment was recorded in Q3 specifically.
- Debt Refinancing: The company fully repaid its $230 million Convertible Senior Notes in April 2025 using proceeds from a new Credit Agreement. As of Q3 2025, the company holds a variable interest rate term loan facility with a principal balance of approximately $161.2 million.
- Restructuring: The company executed two restructuring plans in 2025 (January and August) to optimize cost structure, resulting in workforce reductions across professional services, technology, and sales/marketing.
Guidance, Outlook, and Risks
- Macroeconomic Headwinds: Management cites high inflation, interest rates, and the "One Big Beautiful Bill Act" (OBBBA) signed in July 2025, which is projected to reduce federal Medicaid spending by nearly $1 trillion over 10 years. This is expected to strain client budgets and elongate sales cycles.
- Platform Migration Impact: The migration from the legacy DOS platform to "Health Catalyst Ignite" is creating near-term pressure. While some clients are expanding, an increasing number are opting for price reductions during migration, impacting Dollar-Based Retention.
- Outlook: Management expects Adjusted EBITDA to continue improving annually but acknowledges quarterly fluctuations. They anticipate a higher proportion of gross bookings will come from existing clients (upsells) rather than new platform clients in the near term.
- Risks: Key risks include the inability to compete effectively, failure to execute growth initiatives, client churn during platform migration, and potential further goodwill impairment if stock price declines continue.
Investor Verification Checklist
- Goodwill Valuation: Verify the assumptions used in the Q2 goodwill impairment test and assess the risk of further impairment given the current stock price and market capitalization.
- Migration Economics: Analyze the specific financial impact of the DOS-to-Ignite migration on client retention rates and average contract value (ACV), specifically regarding clients accepting price reductions.
- Debt Covenants: Review the covenants in the new Credit Agreement (Silver Point Finance), specifically the minimum liquidity threshold and leverage ratios, to ensure compliance given the current cash burn.
- Restructuring Savings: Monitor the realization of cost savings from the January and August 2025 restructuring plans against the incurred severance costs.
- Client Concentration: Assess the financial health of the top three clients, which comprised 13.8% of 2024 revenue, given the broader strain on the healthcare system end market.